Sulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation

Background:Heat shock protein 90 (HSP90) has a key role in the maintenance of the cellular proteostasis. However, HSP90 is also involved in stabilisation of oncogenic client proteins and facilitates oncogene addiction and cancer cell survival. The development of HSP90 inhibitors for cancer treatment is an area of growing interest as such agents can affect multiple pathways that are linked to all hallmarks of cancer. This study aimed to test the hypothesis that targeting cysteine residues of HSP90 will lead to degradation of client proteins and inhibition of cancer cell proliferation.Methods:Combining chemical synthesis, biological evaluation, and structure–activity relationship analysis, we identified a new class of HSP90 inhibitors. Click chemistry and protease-mass spectrometry established the sites of modification of the chaperone.Results:The mildly electrophilic sulphoxythiocarbamate alkyne (STCA) selectively targets cysteine residues of HSP90, forming stable thiocarbamate adducts. Without interfering with the ATP-binding ability of the chaperone, STCA destabilises the client proteins RAF1, HER2, CDK1, CHK1, and mutant p53, and decreases proliferation of breast cancer cells. Addition of a phenyl or a tert-butyl group in tandem with the benzyl substituent at nitrogen increased the potency. A new compound, S-4, was identified as the most robust HSP90 inhibitor within a series of 19 derivatives.Conclusion:By virtue of their cysteine reactivity, sulphoxythiocarbamates target HSP90, causing destabilisation of its client oncoproteins and inhibiting cell proliferation.

[1]  G H Snyder,et al.  Electrostatic influence of local cysteine environments on disulfide exchange kinetics. , 1981, Biochemistry.

[2]  L. Neckers,et al.  Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Benias,et al.  A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. , 1998, Journal of immunological methods.

[4]  D. McMillan,et al.  HSF1 is required for extra‐embryonic development, postnatal growth and protection during inflammatory responses in mice , 1999, The EMBO journal.

[5]  H. Itoh,et al.  A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. , 1999, The Biochemical journal.

[6]  L. Neckers,et al.  Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. , 2000, Journal of the National Cancer Institute.

[7]  P. Csermely,et al.  Reactive cysteines of the 90-kDa heat shock protein, Hsp90. , 2000, Archives of biochemistry and biophysics.

[8]  J. Lotem,et al.  Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  L. Neckers,et al.  Hsp90 inhibitors as novel cancer chemotherapeutic agents. , 2002, Trends in molecular medicine.

[10]  Jason C. Young,et al.  The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. , 2003, Molecular endocrinology.

[11]  J. Vázquez,et al.  S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Petersen,et al.  Modification of Heat Shock Protein 90 by 4-Hydroxynonenal in a Rat Model of Chronic Alcoholic Liver Disease , 2005, Journal of Pharmacology and Experimental Therapeutics.

[13]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[14]  N. Kelleher,et al.  A selective chemical probe for coenzyme A-requiring enzymes. , 2007, Angewandte Chemie.

[15]  L. Marnett,et al.  Heat Shock Factor 1 Attenuates 4-Hydroxynonenal-mediated Apoptosis , 2007, Journal of Biological Chemistry.

[16]  W. Linehan,et al.  Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. , 2007, The Journal of urology.

[17]  A. Pettitt,et al.  Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells , 2008, Oncogene.

[18]  L. Marnett,et al.  Identification of protein targets of 4-hydroxynonenal using click chemistry for ex vivo biotinylation of azido and alkynyl derivatives. , 2008, Chemical research in toxicology.

[19]  Johannes Buchner,et al.  Hsp90 is regulated by a switch point in the C‐terminal domain , 2009, EMBO reports.

[20]  Giorgio Colombo,et al.  Modeling Signal Propagation Mechanisms and Ligand-Based Conformational Dynamics of the Hsp90 Molecular Chaperone Full-Length Dimer , 2009, PLoS Comput. Biol..

[21]  S. Lindquist,et al.  HSP90 at the hub of protein homeostasis: emerging mechanistic insights , 2010, Nature Reviews Molecular Cell Biology.

[22]  S. Niture,et al.  Hsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation* , 2010, The Journal of Biological Chemistry.

[23]  G. Giaccone,et al.  Targeting the dynamic HSP90 complex in cancer , 2010, Nature Reviews Cancer.

[24]  Victoria A Johnson,et al.  Macrocyclic inhibitors of hsp90. , 2010, Current topics in medicinal chemistry.

[25]  Lawrence J. Marnett,et al.  Systems Analysis of Protein Modification and Cellular Responses Induced by Electrophile Stress , 2010, Accounts of chemical research.

[26]  R. Cole,et al.  Electrophilic tuning of the chemoprotective natural product sulforaphane , 2010, Proceedings of the National Academy of Sciences.

[27]  S. Larson,et al.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. , 2011, Nature chemical biology.

[28]  Yan Shi,et al.  Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[29]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[30]  Monica A. Chalfant,et al.  Small Molecule Proteostasis Regulators for Protein Conformational Diseases , 2011, Nature chemical biology.

[31]  J. Galligan,et al.  Overview of lipid peroxidation products and hepatic protein modification in alcoholic liver disease. , 2011, Chemico-biological interactions.

[32]  S. Cuzzocrea,et al.  Hormesis, cellular stress response and vitagenes as critical determinants in aging and longevity. , 2011, Molecular aspects of medicine.

[33]  P. Kung,et al.  Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90 , 2011, Clinical Cancer Research.

[34]  C. Glorieux,et al.  Molecular chaperone Hsp90 as a target for oxidant-based anticancer therapies. , 2011, Current medicinal chemistry.

[35]  L. Neckers,et al.  Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy , 2011, Cell cycle.

[36]  I. Benjamin,et al.  HSF1-dependent upregulation of Hsp70 by sulfhydryl-reactive inducers of the KEAP1/NRF2/ARE pathway. , 2011, Chemistry & biology.

[37]  K. Uchida,et al.  Transthiocarbamoylation of Proteins by Thiolated Isothiocyanates* , 2011, The Journal of Biological Chemistry.

[38]  C. Prodromou.  The ‘active life’ of Hsp90 complexes☆ , 2012, Biochimica et biophysica acta.

[39]  Tony Taldone,et al.  Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. , 2012, Biochimica et biophysica acta.

[40]  O. Stoeltzing,et al.  Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. , 2012, Anticancer research.

[41]  K. Morano,et al.  The yeast Hsp70 Ssa1 is a sensor for activation of the heat shock response by thiol-reactive compounds , 2012, Molecular biology of the cell.

[42]  S. Lindquist,et al.  Using the heat-shock response to discover anticancer compounds that target protein homeostasis. , 2011, ACS chemical biology.

[43]  L. Neckers,et al.  Post-translational modifications of Hsp90 and their contributions to chaperone regulation. , 2012, Biochimica et biophysica acta.

[44]  Manway Liu,et al.  The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth , 2013, Molecular Cancer Therapeutics.

[45]  V. Sondak,et al.  Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma , 2013, Molecular Cancer Therapeutics.

[46]  B. Blagg,et al.  Novobiocin analogues with second-generation noviose surrogates. , 2013, Bioorganic & medicinal chemistry letters.

[47]  L. Paz-Ares,et al.  Inhibition of HSP90 molecular chaperones: moving into the clinic. , 2013, The Lancet. Oncology.

[48]  M. Dimopoulos,et al.  Hsp90 inhibitors in breast cancer: a systematic review. , 2013, Breast.

[49]  R. Morimoto,et al.  Regulation of Organismal Proteostasis by Transcellular Chaperone Signaling , 2013, Cell.

[50]  A. Isacchi,et al.  NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases , 2013, Clinical Cancer Research.